Menu
Join us for an enlightening webinar on the evolution of pharmacogenetics, from its historical roots to the impact of groundbreaking innovations and the establishment of specialist foundations. We will explore the introduction of crucial guidelines and annotations that have paved the way for the development of key technologies and solutions in this field. Learn how utilizing next-generation sequencing (NGS) in pharmacogenetics can prevent serious adverse drug reactions and facilitate personalized drug selection and dosing decisions.
Nicolas Picard will share insights into how the French National Network of Pharmacogenetics (RNPGx) is spearheading advancements in pharmacogenetics and how they collaborated with SOPHiA GENETICS to develop a state-of-the-art PGx Solution. Professor Picard will discuss the applications of pharmacogenetics in psychiatry and oncology, presenting practical cases that highlight the real-world impact and value of these advancements.
Featured Presenter:
Nicolas Picard
Professor of Pharmacology, President of RNPGx, Limoges University, France
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
